Trevi Therapeutics, Inc. (TRVI)
11.58
-0.35
(-2.93%)
USD |
NASDAQ |
Apr 01, 16:00
11.60
+0.02
(+0.17%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.446B |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 92.68% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 7.890 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0041 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 95.45% |
Profile
| Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT. |
| URL | http://www.trevitherapeutics.com |
| Investor Relations URL | N/A |
| HQ State/Province | Connecticut |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | May. 07, 2026 (est.) |
| Last Earnings Release | Nov. 13, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT. |
| URL | http://www.trevitherapeutics.com |
| Investor Relations URL | N/A |
| HQ State/Province | Connecticut |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | May. 07, 2026 (est.) |
| Last Earnings Release | Nov. 13, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |